Theriva Biologics, Inc.
TOVX
$0.31
-$0.01-3.58%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 682.84% | -5.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 198.73% | 0.02% | |||
| Operating Income | -198.73% | -0.02% | |||
| Income Before Tax | -201.99% | 2.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -201.99% | 2.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -201.99% | 2.77% | |||
| EBIT | -198.73% | -0.02% | |||
| EBITDA | -199.89% | -0.05% | |||
| EPS Basic | -24.43% | 2.40% | |||
| Normalized Basic EPS | -25.04% | -1.33% | |||
| EPS Diluted | -24.43% | 2.40% | |||
| Normalized Diluted EPS | -25.04% | -1.33% | |||
| Average Basic Shares Outstanding | 142.70% | -0.38% | |||
| Average Diluted Shares Outstanding | 142.70% | -0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||